**Instruction for Use**

**BioFreedom Ultra**

**Drug Coated Coronary Stent System**

**Instruction for Use**

BioFreedom™ Ultra Drug Coated Coronary Stent System

**Table of Content**

[1. DEVICE DESCRIPTION 3](#_Toc470614026)

[1.1. Device Component Description 3](#_Toc470614027)

[1.2. Drug Component Description 5](#_Toc470614028)

[2. INDICATION 5](#_Toc470614029)

[3. CONTRAINDICATIONS 5](#_Toc470614030)

[4. ANTIPLATELET REGIMEN 5](#_Toc470614031)

[5. WARNINGS 6](#_Toc470614032)

[6. PRECAUTIONS 7](#_Toc470614033)

[6.1. Drug Interactions 7](#_Toc470614034)

[6.2. Stent/ System Handling – Precautions 7](#_Toc470614035)

[6.3. Stent Placement – Precautions 8](#_Toc470614036)

[6.4 Stent / System Removal – Precautions 9](#_Toc470614037)

[6.5 Post Implantation – Precautions 9](#_Toc470614038)

[6.6 MRI Information – Precautions 10](#_Toc470614039)

[7 INDIVIDUALISATION OF TREATMENT 10](#_Toc470614040)

[8 USE IN SPECIAL POPULATION 10](#_Toc470614041)

[9 OPERATOR’S MANUAL 10](#_Toc470614042)

[9.1 Inspection Prior to Use 10](#_Toc470614043)

[9.2 Material Required 11](#_Toc470614044)

[9.3 Preparation of the Stent/ Delivery System 11](#_Toc470614045)

[9.4 Stent Delivery Procedure 11](#_Toc470614046)

[9.5 Deployment Procedure 12](#_Toc470614047)

[9.6 Removal Procedure 12](#_Toc470614048)

[9.7 Further dilatation of stent segments 13](#_Toc470614049)

[10 POTENTIAL ADVERSE EVENTS 13](#_Toc470614050)

[11 HOW SUPPLIED 14](#_Toc470614051)

[12 SYMBOLS USED IN LABELING 14](#_Toc470614052)

[13 WARRANTY 15](#_Toc470614053)

1. DEVICE DESCRIPTION

The BioFreedom™ Ultra Drug Coated Coronary Stent System (BioFreedom Ultra DCS) is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9™ (Biolimus A9) and the delivery system.

BioFreedom Ultra DCS is a polymer and carrier free Drug Coated Coronary Stent System.

# Device Component Description

* A balloon expandable coronary cobalt chromium stent per ASTM F562 abluminally coated with the BA9 drug and pre mounted onto a semi-compliant rapid exchange balloon delivery system.
* A delivery system that has two radiopaque markers, which fluoroscopically mark the ends of the stent to facilitate proper placement.
* A female luer lock connector hub located at the proximal end of the delivery system. This hub connects to the balloon inflation lumen.
* The guidewire used in the procedure enters into a port located 27.5cm proximal to the distal tip of the delivery balloon and exits from the distal tip of the balloon catheter.

**Table 1: BioFreedom Ultra Description**

| Stent Pattern | Small Vessel (SV) model | Medium Vessel (MV) model |
| --- | --- | --- |
| Stent Diameters (mm) | 2.25-3.0 | 3.5-4.0 |
| Stent Lengths(mm) | 9, 14, 19, 24, 29, 33\*, 36\* | |
| Stent Material / Coating | CoCr alloy per ASTM F562/ BA9 drug | |
| Delivery Catheter Design | Working Length: 142 cm  Rapid Exchange (RX) compatible with 0.014”guidewires | |
| Guiding catheter compatibility | 5F | |
| Balloon Material | Polyamide Elastomers | |
| Balloon Inflation Pressure  Nominal Pressure (NP)  Rated Burst Pressure (RBP) | 8 atm/811 kPa  16 atm/1621 kPa | 8 atm/811 kPa  14 atm/1418 kPa |
| Balloon deflation time per stent length (see table 3) | 9 & 14 mm: 15 sec  19 to 36 mm: 20 sec | |

*\*(BioFreedom Ultra DCS with a length of 33 and 36 mm are only available for stent diameters from 2.5 to 3.5 mm)*

**Table 2: BioFreedom Ultra stent specifications and BA9 dosage**

| Product Code | Nominal Expanded Inner Diameter(mm) | Nominal Unexpanded Stent Length (mm) | Nominal dose BA9 drug (µg) |
| --- | --- | --- | --- |
| BFC1-2209 | 2.25 | 9 | 148 |
| BFC1-2214 | 2.25 | 14 | 223 |
| BFC1-2219 | 2.25 | 19 | 304 |
| BFC1-2224 | 2.25 | 24 | 381 |
| BFC1-2229 | 2.25 | 29 | 460 |
| BFC1-2509 | 2.50 | 9 | 148 |
| BFC1-2514 | 2.50 | 14 | 223 |
| BFC1-2519 | 2.50 | 19 | 304 |
| BFC1-2524 | 2.50 | 24 | 381 |
| BFC1-2529 | 2.50 | 29 | 460 |
| BFC1-2533 | 2.50 | 33 | 523 |
| BFC1-2536 | 2.50 | 36 | 569 |
| BFC1-2709 | 2.75 | 9 | 148 |
| BFC1-2714 | 2.75 | 14 | 223 |
| BFC1-2719 | 2.75 | 19 | 304 |
| BFC1-2724 | 2.75 | 24 | 381 |
| BFC1-2729 | 2.75 | 29 | 460 |
| BFC1-2733 | 2.75 | 33 | 523 |
| BFC1-2736 | 2.75 | 36 | 569 |
| BFC1-3009 | 3.00 | 9 | 148 |
| BFC1-3014 | 3.00 | 14 | 223 |
| BFC1-3019 | 3.00 | 19 | 304 |
| BFC1-3024 | 3.00 | 24 | 381 |
| BFC1-3029 | 3.00 | 29 | 460 |
| BFC1-3033 | 3.00 | 33 | 523 |
| BFC1-3036 | 3.00 | 36 | 569 |
| BFC1-3509 | 3.50 | 9 | 148 |
| BFC1-3514 | 3.50 | 14 | 223 |
| BFC1-3519 | 3.50 | 19 | 304 |
| BFC1-3524 | 3.50 | 24 | 381 |
| BFC1-3529 | 3.50 | 29 | 460 |
| BFC1-3533 | 3.50 | 33 | 523 |
| BFC1-3536 | 3.50 | 36 | 569 |
| BFC1-4009 | 4.00 | 9 | 148 |
| BFC1-4014 | 4.00 | 14 | 223 |
| BFC1-4019 | 4.00 | 19 | 304 |
| BFC1-4024 | 4.00 | 24 | 381 |
| BFC1-4029 | 4.00 | 29 | 460 |

# Drug Component Description

The BA9 drug (USAN/INN: *umirolimus*) is a semi-synthetic sirolimus derivative with high lipophilicity. The BA9 drug, as provided on the BioFreedom Ultra DCS, inhibits smooth muscle cell proliferation to reduce restenosis.

The drug coating consists of the active ingredient BA9 (Biolimus A9), which is applied to the abluminal surface of the stent with no polymer or carrier.

Refer to Table 2 for the nominal dose of BA9 per stent.

1. INDICATION

The BioFreedom Ultra DCS is indicated for improving coronary luminal diameter for the treatment of de novo lesions in native coronary arteries with a reference diameter ranging from 2.25mm to 4.0mm. Stents with lengths of 33mm and 36mm are only available for artery diameters ranging between 2.5mm and 3.5mm.

1. CONTRAINDICATIONS

The BioFreedom Ultra DCS is contraindicated for use in:

* Patients in whom antiplatelet and/ or anticoagulation therapy is contraindicated.
* Patients with lesion(s) that prevent complete inflation of an angioplasty balloon.
* Patients with known sensitivity to BA9 or its derivatives.
* Patients with known allergies to Cobalt, Chromium, Nickel, Molybdenum or any metallic component used in CoCr ASTM F562 alloy.
* Patients with known sensitivity to contrast agents that cannot be controlled prophylactically prior to BioFreedom Ultra stent implantation.
* Off-label use (i.e.: outside of the approved indication for use).

1. ANTIPLATELET REGIMEN

Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical for a good long term result of the implantation.

Physicians should take into consideration information from clinical trials with BA9 DCS[[1]](#footnote-1),[[2]](#footnote-2),[[3]](#footnote-3), other BA9 DES trials[[4]](#footnote-4),[[5]](#footnote-5),[[6]](#footnote-6) as well as the most recently updated ESC/AHA/ACC/SCAI Guidelines for percutaneous coronary intervention and the specific needs of individual patients to determine the optimal antiplatelet/ anticoagulation regimen to be used for their patients.

Additionally, in patients with high bleeding risk (HBR), physicians may choose a 1-month dual antiplatelet regimen based on the results of the randomized, double-blind LEADERS FREE1 trial conducted in 2,466 PCI patients which demonstrated superior safety and efficacy outcomes for the BA9 DCS versus a BMS with one month of dual antiplatelet therapy followed by single antiplatelet therapy alone.

High bleeding risk (HBR) may include patients with any of the following:

* >75 years old
* Oral anticoagulation use (including vitamin-K antagonists or factor Xa-inhibiting drugs) planned to continue for >1 month post PCI
* Hemoglobin <11 g/dL or anemia requiring transfusion in the previous month
* Platelet count <100,000/mm3 in the previous month
* Hospital admission for bleeding in the previous 12 months
* Stroke in the previous 12 months
* Any prior intracerebral hemorrhage
* Severe chronic liver disease defined to include the following diseases or symptoms: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice
* Creatinine clearance <40 ml/min in the previous month
* Cancer (non-skin) in the previous 3 years
* Major surgery planned in the 12 months post-PCI
* Glucocorticoids or NSAID planned to continue >1 month post-PCI
* Other medical reasons that would preclude treatment with >1 month dual antiplatelet therapy.

Physicians should consider the bleeding versus ischemic risk when determining the most beneficial antiplatelet regimen for an individual patient.

1. WARNINGS

* Judicious selection of patients is necessary since the use of this device carries the associated risk of thrombosis, vascular complications and/ or bleeding events. Hence, patients should be maintained on clinically adequate post-procedural antiplatelet therapy (Refer to section 4.0: Antiplatelet regimen).
* Only physicians who have received appropriate training should perform implantation of the stent.
* Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
* Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized stents is unknown at present.
* Use of the device in patients with history of restenosis, multiple stents, and diabetes can lead to an increased risk of restenosis.
* The extent of residual stenosis can lead to a greater risk of restenosis.
* The presence of malapposition may increase the risk of stent thrombosis.
* Ensure that the inner packaging has not been damaged or opened as this may indicate a breach of the sterile barrier.
* **This stent delivery system must not be reused in another procedure**. The performance characteristics of the balloon are degraded during use.
* This product is not intended or approved for use in peripheral arteries.
* When overlapping stents are implanted, stent materials should be of similar composition to avoid dissimilar metal corrosion.
* Direct stenting has not been evaluated in clinical studies using the BioFreedom Ultra stent. Therefore, direct stenting is not recommended (refer to section 9.4, stent delivery procedure).
* DO NOT resterilize and/ or reuse this device or related delivery system, as this can compromise performance and can lead to device/ delivery system failure and procedural complications with severe injury or patient death. Reuse, reprocessing and resterilization bear the risk of cross contamination and patient to patient infection.
* The “crushing” technique in bifurcations has not been sufficiently studied with BioFreedom Ultra DCS. No information is available regarding BioFreedom Ultra DCS abluminal surface exposure to the blood stream.

1. PRECAUTIONS

# Drug Interactions

* Consideration should be given to the potential for drug interactions when deciding to place a BioFreedom Ultra stent in a patient who is taking a drug that could interact with the BA9 drug or when deciding to initiate therapy with such a drug in a patient who has recently received a stent coated with BA9 drug. The effect of the BioFreedom Ultra DCS drug interactions on safety or efficacy has not been determined.
* There is no specific clinical data available for the interaction of the BA9 drug with other drugs. However, drugs like Tacrolimus that may act through the same binding proteins (FKBP) may interfere with the efficacy of the BA9 drug. Drug interaction studies have not been performed.
* The BA9 drug is metabolized by CYP3A4. Strong inhibitors of CYP3A4 (e.g. ketoconazol) might cause increased BA9 drug exposure to levels associated with systemic effects, especially if multiple stents are deployed. Systemic exposure of BA9 drug should be taken into consideration if the patient is treated concomitantly with systemic immunosuppressive therapy.
* Patient’s systemic exposure to the BA9 drug is directly related to the number and length of the BioFreedom Ultra stent or any other BA9 eluting stents implanted.

# Stent/ System Handling – Precautions

* For **single use only**. Do not resterilize or reuse.
* Do not use a product that has reached or exceeded its labeled expiration date.
* Do not use if package is opened or damaged. **The sterility and stability of the BioFreedom Ultra DCS cannot be guaranteed once the pouch has been opened** and the device MUST be used promptly. Un-used devices should be returned to Biosensors International[[7]](#footnote-7) and should not be re-stocked.
* The delivery system is designed to deploy the stent once, and cannot be reused.
* Do not use if the stent coating is subjected to abrasions beyond those of normal insertion and delivery.
* Do not use if the stent is exposed to abnormal rubbing or contact with objects other than the guide catheter or opened hemostasis valve prior to implantation.
* **Do not rub or scrape the stent coating.**
* Do not remove stent from its delivery catheter as removal may damage the stent and/ or lead to stent embolization. BioFreedom Ultra DCS is intended to perform as a system.
* Special care must be taken not to handle or in any way disrupt the stent on the balloon as this action may loosen the stent from the balloon and cause subsequent dislodgement, or some loss of the drug coating.
* Exposing the stent to fluids before implantation is not recommended. Exposure to fluids prior to implantation may result in premature release of drug.
* Use only the appropriate balloon inflation media (contrast media in dilution 1:1 with normal saline). Do not use air or any gaseous medium to inflate the balloon as this may cause uneven expansion and difficulty in deployment of the stent.
* The delivery system should not be used in conjunction with other stents.
* Do not attempt to straighten the proximal shaft (hypotube) as it may cause the catheter to break if it is accidentally bent.
* When removing the device from the packaging, care should be taken not to kink the shaft.
* Do not expose BioFreedom Ultra to organic solvents, e.g. isopropyl alcohol. Such an exposure can degrade BioFreedom Ultra performance.
* In the event that the stent is not successfully deployed, the stent and delivery system should be returned to Biosensors International7.
  1. Stent Placement – Precautions
* **Do not prepare, introduce negative pressure or pre-inflate the delivery system prior to stent deployment** other than as directed. Use balloon purging technique described in section 9.5 Deployment Procedure.
* **The labeled stent diameter refers to the expanded stent inner** diameter at its nominal pressure.
* Implanting a stent may lead to dissection of the vessels distal and/ or proximal to the stent and may cause acute closure of the vessel, requiring additional intervention (e.g. further dilatation, placement of additional stents, or CABG).
* When treating multiple lesions, distal lesions should be stented first followed by proximal lesions. Stenting in this order obviates the need to cross the proximal stent when placing the distal stent and reduces the chances for dislodging the proximal stent.
* Do not expand the device if proper positioning of the stent within the lesion cannot be achieved (See 6.4. Stent / System Removal – Precautions).
* Placement of a stent has the potential to compromise side branch patency.
* **Do not exceed rated burst pressure as indicated on product labeling material.** Use of pressures higher than specified on the product labeling material may result in a ruptured balloon with possible intima damage and dissection. Over inflation may lead to stent fracture.
* **Use particular caution when pulling back an unexpanded stent into the guiding catheter, as dislodgement of the stent from the balloon may occur. Remove as a single unit as described in section 6.4 Stent/System Removal Precautions.**
* Stent retrieval methods (use of additional wires, snares and/ or forceps) may result in additional trauma to the coronary vasculature and/ or the vascular access site. Complications may include bleeding, hematoma or pseudoaneurysm.
  1. Stent / System Removal – Precautions

Should unusual resistance be felt at any time during either ante-grade advancement of the stent or during removal of the stent delivery system into the guiding catheter if the stent failed to be implanted, the entire system should be removed as a single unit (see below). This must be done under direct fluoroscopic visualization.

**When removing the stent delivery system as a single unit:**

* Do not attempt to retract an unexpanded stent into the guiding catheter/ introducer sheath as stent or coating damage or stent dislodgment from the balloon may occur.
* Ensure complete balloon deflation. If unusual resistance is felt during stent delivery system withdrawal, pay particular attention to the guiding catheter position. In some cases it may be necessary to slightly retract the guiding catheter in order to prevent unplanned guiding catheter movement and subsequent vessel damage. In cases where unplanned guiding catheter movement has occurred, a coronary tree angiographic assessment should be undertaken to ensure that there is no damage to the coronary vasculature.
* Position the proximal balloon marker just distal to the guiding catheter tip.
* Advance the guidewire into the coronary anatomy as far distally as safely possible. **NOTE**: If this is necessary to maintain guidewire position, the guidewire must either be converted to an exchange wire length or a second guidewire must be inserted.
* Tighten the rotating hemostatic valve to secure the delivery system to the guiding catheter. Remove the guiding catheter and stent delivery system as a **single unit.**
* **When the distal tip of the guiding catheter reach the distal end of the introducer sheath, remove sheath, guiding catheter, and delivery system as a single unit and replace sheath as per hospital protocol.**
* Stent retrieval methods (use of additional wires, snares and/or forceps) may result in additional trauma to the coronary vasculature and/or the vascular access site. Complications may include bleeding, hematoma or pseudoaneurysm.

Failure to follow these steps and/ or applying excessive force to the stent delivery system can potentially result in vessel damage, stent dislodgement or damage to the stent and/ or delivery system components.

* 1. Post Implantation – Precautions

Care must be exercised when crossing a newly deployed stent with adjunct devices to avoid disrupting stent placement, apposition, and/ or geometry.

* 1. MRI Information – Precautions

CoCr (ASTM F562) as used in BioFreedom Ultra DCS is a non ferromagnetic alloy that does not interact with MRI. Non-clinical testing has demonstrated that the BioFreedom DCS is MR Conditional. . A patient with a BioFreedom Ultra stent can be scanned safely, immediately after placement of this implant, under the following conditions:

* Static magnetic field of 1.5-Tesla and 3-Tesla[[8]](#footnote-8) only
* Maximum spatial gradient field of 3000 gauss/cm (30.0 T/m)
* Maximum MR system reported whole-body-averaged specific absorption rate (SAR) of <2.0 W/kg for 15 minutes of scanning.

**MRI related heating test:**

Under the scan conditions defined above, the BioFreedom™ Ultra Drug Coated Coronary Stent is expected to produce a maximum temperature rise of 2.72°C after 15 minutes of continuous scanning[[9]](#footnote-9).

**Image Artifact:**

In non-clinical testing, the image artifact caused by the device extends approximately 7mm from the BioFreedom Ultra stent when imaged with a *gradient echo* pulse sequence and a 3T MRI system.

1. INDIVIDUALISATION OF TREATMENT

The risks and benefits of drug eluting or drug coated stents should be considered for each patient before use of the BioFreedom Ultra stent. Physicians are responsible for assessing patient appropriateness for stent implantation prior to procedure.

1. USE IN SPECIAL POPULATION

The safety and effectiveness of the BioFreedom Ultra stent has not been established in the following patient populations.

* Pregnancy: There is no data available for use of the BioFreedom Ultra stent in pregnant women.
* During Lactation: The effects of the BA9 drug during lactation have not been evaluated.
* Pediatric use: The safety and efficacy of the BioFreedom Ultra stent has not been established.

Carefully consider whether it is appropriate to use the BioFreedom Ultra stent in the above patient populations.

1. OPERATOR’S MANUAL

# Inspection Prior to Use

1. Verify expiration date and inspect the stent delivery system package for damage to the sterile barrier before opening. Do not use after the expiration date. If the integrity of the sterile package has been compromised (e.g., damage to the package), contact Biosensors. Do not use if any defects are noted.
2. Carefully remove the system from the package and inspect the delivery catheter for bends, kinks, and other damage.

Carefully remove the stent guard covering the stent/ balloon. The pre-attached stylet is automatically removed.

1. Inspect the stent to ensure that it has not been damaged or displaced from its original position on the balloon. Verify that the stent is positioned between proximal and distal balloon markers.
2. Note the position of the stent relative to the delivery system markers for use as reference under fluoroscopy.

Do not use if any defects are noted.

# Material Required

|  |  |
| --- | --- |
| 1 | Appropriate guiding catheter with minimum inner diameter of 0.056”/ 1.42 mm for all stent sizes |
| 1 | Pre-dilatation balloon catheter |
| 1 | 10-20 ml syringe |
| 1000 IU | Heparin per 500 ml Normal Saline (HepNS) |
| 1 | Guidewire, 0.014 inch/ 0.36 mm maximum diameter x 190 cm minimum length |
| 1 | Rotating hemostatic valve |
| N/A | Contrast medium diluted 1:1 with normal saline |
| 1 | Inflation device |
| 1 | Three-way stopcock |

# Preparation of the Stent/ Delivery System

1. Prepare inflation device/ syringe with diluted contrast medium.
2. Attach the inflation device to the three-way stopcock; attach to balloon inflation port hub. DO NOT apply negative or positive pressure to the balloon at this time as it can cause premature dislodgement of the stent.
3. Open stopcock to stent delivery system.
4. Leave on neutral.

# Stent Delivery Procedure

1. Prepare vascular access site according to standard PTCA practice.
2. Pre-dilate lesion with a balloon diameter 0.5 mm smaller than the stent and a balloon length equal to or shorter than the target lesion length and shorter than the length of the stent to be implanted.

NOTE: The safety of using the mechanical atherectomy devices (directional atherectomy catheters) or laser angioplasty catheters to treat in-stent stenosis has not been established.

1. Immediately prior to back loading the stent delivery catheter onto the guidewire, flush the guidewire lumen of the delivery system with HepNS according to hospital protocol. Avoid contact with the stent.

**NOTE:** Stent contact with fluid has the possibility of initiating drug release. Fluid contact time should be avoided prior to loading the delivery system in the patient.

1. Backload stent delivery system onto the proximal portion of the guidewire while maintaining guidewire position across target lesion.
2. Open rotating hemostatic valve on the guiding catheter hub as widely as possible and close when the stent has been advanced safely inside the guide catheter.
3. Advance the stent delivery system over the guidewire to the target lesion under fluoroscopic guidance. Utilize the radiopaque balloon markers to position the stent across the lesion. Perform angiography to confirm stent position, if needed.

**NOTE:** If resistance is felt, DO NOT FORCE PASSAGE. Resistance may indicate a problem and may result in damage to the vessel or stent, or in stent dislodgement if it is forced. Remove the stent delivery system and the guiding catheter with particular caution to avoid further technical problems as a single unit (see 6.4. Stent/ Stent System Removal - Precautions).

# Deployment Procedure

1. Consult the product labeling material in order to determine the balloon inflation pressure appropriate for the target vessel diameter.

**CAUTION**: **Different compliance charts apply for different stent lengths.**

1. Before deployment, reconfirm the correct position of the stent relative to the target lesion via the balloon markers.
2. Ensure that the three-way stopcock on the stent delivery system is open to the inflation device and apply negative pressure to purge the balloon of air.
3. Turn the three-way stopcock on the stent delivery catheter off to the balloon port and purge the inflation device of air. Open the side port of the three-way stopcock to the delivery system.
4. Under fluoroscopic visualization, inflate the balloon to at least 8 atm to deploy the stent, but do not exceed the labeled rated burst pressure (RBP). Optimal expansion requires the stent to be in full contact with the artery wall with the stent internal diameter matching the size of the reference vessel diameter. **ENSURE THAT THE STENT IS NOT UNDER-EXPANDED**.
5. Deflate the balloon by pulling a vacuum with the inflation device. Make sure the balloon is fully deflated before attempting any movement of the system. Please refer to below table for deflation time per product stent length.

**Table 3: BioFreedom Ultra balloon deflation time per product specification**

|  |  |
| --- | --- |
| Stent length [mm] | Time for deflation [s] |
| 9 & 14 | ≤ 15 |
| 19 to 36 | ≤ 20 |

1. Confirm adequate stent expansion and balloon deflation by angiographic injection through the guiding catheter.
2. If more than one BioFreedom Ultra stent is needed to cover the lesion and balloon treated area, adequately overlap the stents (at least 2 mm) to avoid potential gap stenosis.

# Removal Procedure

1. Ensure that the balloon is fully deflated.
2. Fully open the rotating hemostatic valve.
3. While maintaining guidewire position and negative pressure on inflation device, withdraw the delivery system.
4. Tighten rotating hemostatic valve.
5. Repeat angiography to assess the stented area.

# Further dilatation of stent segments

1. If an adequate expansion has not been obtained, consider post-dilatation with another balloon catheter of appropriate balloon diameter to achieve proper stent apposition to the vessel wall.

**NOTE:** Post-dilatation should be performed within the stented segment if needed as per operator assessment. DO NOT dilate beyond the stent edges.

1. Reconfirm stent position and angiographic result. Repeat inflations until optimal stent deployment is achieved. Final stent diameter should match reference vessel.
2. POTENTIAL ADVERSE EVENTS

Adverse events that may be associated with the use of a stent in native coronary arteries include but not limited to:

* Abrupt vessel closure or spasm
* Acute myocardial infarction
* Allergic reaction to anti-coagulation and/ or anti-thrombotic therapy, contrast material, the stent and/ or delivery system materials
* Aneurysm, pseudoaneurysm or arteriovenous fistula
* Arrhythmias, including ventricular fibrillation and ventricular tachycardia
* Bradycardia requiring pharmacologic intervention
* Cardiac tamponade
* Cardiogenic shock
* Death
* Dissection, perforation, or rupture of the artery
* Emboli, distal (air, tissue or thrombotic emboli)
* Emergency coronary artery bypass grafting (CABG) as a result of damage to the stent or injury to the vessel
* Fever
* Hematoma at insertion site
* Hemorrhage requiring transfusion
* Hypotension/ hypertension
* Infection and/ or pain at insertion site
* Perforation or rupture of the artery
* Peripheral ischemia or peripheral nerve injury
* Stent thrombosis/ occlusion
* Stent migration or stent embolization
* Stroke or transient ischemic attack
* Renal failure
* Restenosis of stented segment
* Total occlusion of coronary artery
* Unstable angina

**Adverse events that may be associated with BA9 drug coating:**

**NOTE:** BA9 drug administration is limited to intra-coronary stent delivery. The adverse effects of using this drug have not been fully characterized. Although not observed so far with BA9 stents, side effects experienced with substantially higher BA9 doses following systemic drug application may include the following:

* Nausea
* Lymphadenopathy
* Mouth ulcers
* Chest Heaviness
* Dizziness

1. HOW SUPPLIED

STERILE**:** Package contents are sterile unless package is opened or damaged. This device is sterilized via electron beam radiation and is non-pyrogenic. **It is intended for single use only**. Do not use if package is open or damaged.

CONTENTS**:** One BioFreedom Ultra Drug Coated Coronary Stent System, and one Instruction for Use.

STORAGE**:** Store in a cool, dark, dry place. Do not store above 30°C.

DISPOSAL: Dispose device in accordance with local regulation.

NOTE: This product does not contain phthalates and latex.

1. SYMBOLS USED IN LABELING

|  |  |  |  |
| --- | --- | --- | --- |
| Manufacturer | Legal Manufacturer |  | Keep away from sunlight or heat |
| http://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm085708.gif | Date of Manufacture | keep dry | Keep Dry |
| ref | Catalog number | damaged pkg | Do not use if package is damaged or open |
| lot | Batch code |  | Stent Length |
| See manual symbol | Caution, consult accompanying documents | maximum | Stent Diameter |
|  | Do not re-sterilize |  | Maximum Guidewire Outer Diameter (OD): |
| do not reuse | Do not reuse | minimum | Minimum Guiding Catheter Inner Diameter (ID): |
| steriliz | This product has been sterilized using irradiation | temperature limitation 30C.jpg | Do not store above 30°C |
|  | Use by date  Do not use this device after the indicated date (Year-month-day): |  | Consult Instruction for use |
| NP | Nominal Pressure | RBP | Rated Burst Pressure |
| cid:image007.png@01CC35C7.A0594230 | MR Conditional |  | Non-pyrogenic |

1. WARRANTY

Legal manufacturer warrants that its products are manufactured to the specifications set forth on its packaging, instructions for use and related literature.

This warranty is in lieu of and excludes all other warranties not expressly set forth herein, whether expressed or implied, by operation of law or otherwise, including, but not limited to, any implied warranties of merchantability or fitness for a particular purpose.

Legal manufacturer neither assumes, nor authorizes any other person to assume for it, any other or additional liability or responsibility in connection with this product.

1. Urban P. et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. New England Journal of Medicine

   2015, October 14, DOI: 10.1056/NEJMoa1503943 [↑](#footnote-ref-1)
2. Garot, P. *et al.* 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. *J. Am. Coll. Cardiol.* **69**, 162–171 (2017). [↑](#footnote-ref-2)
3. Ricardo A. Costa et al.: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions (2015), doi: 10.1016/j.jcin.2015.09.008. [↑](#footnote-ref-3)
4. Windecker S, Serruys PW, Wandel S and al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomized non-inferiority trial. The Lancet: Published online September 1st, 2008 [↑](#footnote-ref-4)
5. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. [Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.](http://www.ncbi.nlm.nih.gov/pubmed/22075451) Lancet. 2011 Dec 3;378(9807):1940-8. [↑](#footnote-ref-5)
6. Serruys PW et al. Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report of the LEADERS (Limus Eluted From A Durable Versus Erodable Stent Coating) Randomized, Non-inferiority Trial. JACC : Cardiovascular Interventions, vol 6, n°8, 2013 [↑](#footnote-ref-6)
7. Please contact the Sales and Customer Service of your region or local distributor for return of goods [↑](#footnote-ref-7)
8. Shellock FG, Forder JR. Drug eluting coronary stent: In vitro evaluation of Magnetic Resonance safety at 3 Tesla. Journal of Cardiovascular Magnetic Resonance. 2005;7 415-419 [↑](#footnote-ref-8)
9. Non-clinical evaluation performed with BioFreedom Ultra 3.5 mm diameter stents at the overlapped length of 70 mm [↑](#footnote-ref-9)